Keyword

ipilimumab

Description: A monoclonal antibody drug that blocks CTLA-4 and is used as an immune checkpoint inhibitor in cancer treatment.

Primary topic: Cancer Immunotherapy and Biomarkers (61%)

Wikidata ID: wiki/Q2459042

OpenAlex ID: keywords/ipilimumab

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 · Rimda Wanchoo, Sabine Karam, et al. · American Journal of Nephrology · 15,256

PDF

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 · F. Stephen Hodi, Steven J. O'Day, et al. · New England Journal of Medicine · 15,161

PDF

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

2015 · James Larkin, Vanna Chiarion-Sileni, et al. · New England Journal of Medicine · 8,143

PDF

Pembrolizumab versus Ipilimumab in Advanced Melanoma

2015 · Caroline Robert, Jacob Schachter, et al. · New England Journal of Medicine · 5,884

PDF

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2017 · Jedd D. Wolchok, Vanna Chiarion-Sileni, et al. · New England Journal of Medicine · 5,351

PDF

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2011 · Caroline Robert, Luc Thomas, et al. · New England Journal of Medicine · 4,502

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

2014 · Alexandra Snyder, Vladimir Makarov, et al. · New England Journal of Medicine · 4,282

PDF

Nivolumab plus Ipilimumab in Advanced Melanoma

2013 · Jedd D. Wolchok, Harriet Kluger, et al. · New England Journal of Medicine · 4,230

PDF

Cancer immunotherapy comes of age

2011 · Ira Mellman, George Coukos, et al. · Nature · 3,888

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2019 · James Larkin, Vanna Chiarion-Sileni, et al. · New England Journal of Medicine · 3,715

PDF

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2013 · Omid Hamid, Caroline Robert, et al. · New England Journal of Medicine · 3,396

PDF

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 · Jedd D. Wolchok, Axel Hoos, et al. · Clinical Cancer Research · 3,223

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

2021 · Yelena Y Janjigian, Kohei Shitara, et al. · The Lancet · 3,067

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

2018 · Matthew D. Hellmann, Tudor-Eliade Ciuleanu, et al. · New England Journal of Medicine · 3,062

PDF

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

2015 · Eliezer M. Van Allen, Diana Miao, et al. · Science · 2,837

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

2019 · Matthew D. Hellmann, Luis Paz-Ares, et al. · New England Journal of Medicine · 2,820

PDF

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

2015 · Michael A. Postow, Jason Chesney, et al. · New England Journal of Medicine · 2,784

PDF

Immune Checkpoint Blockade in Cancer Therapy

2015 · Michael A. Postow, Margaret K. Callahan, et al. · Journal of Clinical Oncology · 2,748

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

2015 · Jeffrey S Weber, Sandra P D'Angelo, et al. · The Lancet Oncology · 2,676

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

2018 · Daniel Y. Wang, Joe-Elie Salem, et al. · JAMA Oncology · 2,669

PDF

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

2017 · Nadeem Riaz, Jonathan J. Havel, et al. · Cell · 2,388

PDF

CTLA-4 and PD-1 Pathways

2015 · Elizabeth I. Buchbinder, Anupam Desai · American Journal of Clinical Oncology · 2,357

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

2016 · Douglas B. Johnson, Justin M. Balko, et al. · New England Journal of Medicine · 2,304

PDF

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

2017 · Jeffrey Weber, Mario Mandala, et al. · New England Journal of Medicine · 2,245

PDF

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

2015 · Dirk Schadendorf, F. Stephen Hodi, et al. · Journal of Clinical Oncology · 2,141

PDF

Works count: 17,110

Citation count: 453,800